mRNA Vaccine Market Analysis

mRNA Vaccine Market Analysis

To get key market trends

  Download Free Sample

By type, the mRNA vaccine market is classified into self-amplifying mRNA vaccines and conventional non-amplifying mRNA vaccines. The self-amplifying mRNA vaccines segment accounted for 50.9% of the business share in 2022 and is projected to witness robust growth over the analysis timeframe. The self-amplifying mRNA vaccines replicate within cells and enable to attain higher antigen production resulting in a more potent immune response and improved vaccine efficacy. Additionally, self-amplifying mRNA vaccines can achieve a dose-sparing effect requiring lower vaccine doses while still eliciting robust immune responses.
 

Furthermore, they offer flexibility in targeting various infectious diseases and can be adapted to express antigens from different pathogens, making it applicable to a range of viral, bacterial, parasitic diseases. Such advantages associated with self-amplifying mRNA vaccines is predictable to propel the market expansion.
 

The end-use in mRNA vaccine market is categorized into hospitals & clinics, research laboratories and other end-users. Hospitals & clinics segment accounted for USD 7.1 billion in 2022. Availability of skilled medical professionals and advanced healthcare infrastructure has propelled the hospitals & clinics segment progress. Also, hospitals offer accessibility and convenience for individuals seeking vaccination during their regular visits for healthcare needs. Furthermore, developed infrastructure and well-established storage facilities contributes to streamlined operations and reduces the risk of vaccine shortage as well as wastage in the hospital & clinics.
 

North America mRNA vaccine market accounted for over 42.4% revenue share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. The increasing prevalence of infectious diseases and rising adoption of advanced medical technologies is estimated to drive the market forecasts. Furthermore, presence of well-established healthcare infrastructure, key market players and research activities contribute to the growth of mRNA vaccine research & development. Moreover, growing demand for preventive healthcare, rising government investments in R&D will further support the of market growth in the North America region.